Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Squamous Cell 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Head and Neck Neoplasms 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Solid Tumor 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Esophageal Squamous Cell Carcinoma 1Epidermolysis Bullosa Dystrophica 1

Interventions

fludarabine phosphate 60Cyclophosphamide 60Busulfan 43Cyclosporine 41Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Cytarabine 36Whole-Body Irradiation 34Antilymphocyte Serum 29Filgrastim 26Tacrolimus 24Methotrexate 24fludarabine 23Cord Blood Stem Cell Transplantation 22Radiotherapy 21Melphalan 20Etoposide 18Methylprednisolone 15Azacitidine 14Granulocyte Colony-Stimulating Factor 13Idarubicin 12Daunorubicin 11Thiotepa 10sargramostim 8Cyclosporins 8Clofarabine 7Arsenic Trioxide 7Transplantation 6Topotecan 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × ON 01910 × Clear all
NCT01241500 2020-06-30

ONTIME

Traws Pharma, Inc.

Phase 3 Completed
299 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Traws Pharma, Inc.

Phase 3 Completed
67 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡